Clofibric acid

SKU: orb1310980

Description

Clofibric acid

Research Area

Infectious Disease & Virology, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 882-09-7
• MW: 214.65
• Purity: 99.47% (May vary between batches)
• Formula: C₁₀H₁₁ClO₃
• SMILES: CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
• Target: Antibacterial,PPAR,Drug Metabolite
• Solubility: DMSO:250 mg/mL (1164.69 mM);Ethanol:40 mg/mL (186.35 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (9.32 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• In Vivo:
  Clofibric acid enhances the expression of the CYP4A6 gene in RK13 cells transfected with PPAR-Gamma.
• In Vitro:
  Clofibric acid enhances the expression of carbonyl reductase in vivo, reduces PGE2 levels, and diminishes the quantity of vascular endothelial growth factor (VEGF) in OVCAR-3 tumors and DISS-origin ascites. In solid OVCAR-3 tumors, it decreases microvascular density and induces apoptosis. Compared to the control, a 9,000 ppm Clofibric acid diet significantly reduces the growth of OVCAR-3 tumor xenografts s.c. by 46% and notably prolongs the survival of mice with DISS-origin malignant ascites.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PPAR, Peroxisome proliferator-activated receptors, DrugMetabolite, Drug Metabolite, Chlorofibrinic acid, Clofibric acid, Inhibitor, inhibit

Compound Identifiers

PubChem CID

2797